BNGO BIONANO GENOMICS INC

Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress.

Conference Call & Webcast Details

Date:Monday, March 31st, 2025
Time:4:30 p.m. ET
Participant Link:
Webcast Link:

Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at  for at least 30 days.

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610



EN
14/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE

Bionano Announces Publication Showing OGM can Provide an Accurate and ...

Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud Un...

 PRESS RELEASE

Bionano Announces French Publication of an Effective Method for Analys...

Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic b...

 PRESS RELEASE

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides...

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 Conference call today, March 31, 2025 at 4:30 PM ET SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our missi...

 PRESS RELEASE

Study Using OGM in Neural Tube Defects Reveals Previously Unreported V...

Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) and Greenwood Genetic Center (GGC) today announced a publication in Genome Research describing the first study to use optical genome mapping (OGM) to investigate the genetic landscape of neural tube defects (NTDs). NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. ...

 PRESS RELEASE

Bionano Announces Extensive Lineup of Content at American College of M...

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuing medical education (CME) session, with a panel of experts presenting research on OGM's clinical and translational applications. Dr. Adam Smith (University of Toronto, Canada; currently at Labcorp, USA) will provide an overview of OGM’s evolution into an essential tool for hematological malignancy research ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch